- Home
- MA vs TMO Comparison
MA vs TMO Comparison
Compare MA & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MA | TMO |
|---|---|---|
| Founded | 1966 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Industrial Machinery/Components |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.9B | 164.3B |
| IPO Year | 2005 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MA | TMO |
|---|---|---|
| Price | $495.24 | $494.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 18 |
| Target Price | ★ $649.19 | $636.00 |
| AVG Volume (30 Days) | ★ 3.2M | 2.4M |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | ★ 0.66% | 0.40% |
| EPS Growth | ★ 18.93 | 7.32 |
| EPS | 4.35 | ★ 4.43 |
| Revenue | ★ $32,791,000,000.00 | $20,918,000,000.00 |
| Revenue This Year | $16.19 | $6.55 |
| Revenue Next Year | $12.35 | $5.11 |
| P/E Ratio | $111.49 | ★ $105.98 |
| Revenue Growth | ★ 16.42 | 14.47 |
| 52 Week Low | $464.52 | $385.46 |
| 52 Week High | $601.77 | $643.99 |
Technical Indicators
Market Signals| Indicator | MA | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 58.37 |
| Support Level | $487.11 | $456.87 |
| Resistance Level | $529.49 | $501.13 |
| Average True Range (ATR) | 9.78 | 13.58 |
| MACD | 0.06 | 3.37 |
| Stochastic Oscillator | 74.50 | 87.22 |
Price Performance
Historical ComparisonAbout MA Mastercard Incorporated
Mastercard is the second-largest payment processor in the world, having processed close to $11 trillion in volume during 2025. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).